Title

Effect and safety of immune checkpoint inhibitors in metastatic lung cancer: A retrospective study

Authors

Arvind Kumar^*,1, Arun Raja¹ & Dipika Narayan²

Affiliation

¹Department of General Medicine & Medical Oncology, Near Sudha Dairy, Bokaro General Hospital, Biada Housing Colony, Ritudih, Bokaro Steel City, Jharkhand - 827012, India; ²Department of General Medicine, Bokaro General Hospital, Bokaro Steel City - 827004, Jharkhand, India; *Corresponding author

Email

Arvind Kumar - E - mail: arvind19kumar70@gmail.com
Arun Raja - E - mail: drarunrajaonco@gmail.com
Dipika Narayan - E - mail: deepikanarayan3@gmail.com

Article Type

Research Article

Date

Received March 1, 2025; Revised March 31, 2025; Accepted March 31, 2025, Published March 31, 2025

Abstract

Cancer is a major global public health issue. Immune checkpoint inhibitors are increasingly used for managing advanced malignancies. However, their effect is limited by immune-related adverse events. Hence, a retrospective, single-institutional study found a 60% clinical benefit ratio among 30 patients receiving Immune checkpoint inhibitors therapy. Nonetheless, a small sample size, patient heterogeneity and retrospective design require further validation for more conclusive results.

Keywords

Non-Small Cell Lung Cancer, immunotherapy, nivolumab, real-life and efficacy.

Citation

Kumar et al. Bioinformation 21(3): 534-537 (2025)

Edited by

Neelam Goyal & Shruti Dabi

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.